Standard Treatment Duration for Sivextro
Sivextro (tedizolid phosphate) treats acute bacterial skin and skin structure infections (ABSSSI) in adults. The standard course is 6 days, given once daily, either orally or intravenously.[1]
How Sivextro Dosing Works
Each dose is 200 mg. Patients can switch from IV to oral mid-course if improving. Total duration stays at 6 days, shorter than vancomycin's typical 7-14 days for similar infections.[1][2]
When Might Treatment Differ?
Guidelines stick to 6 days for uncomplicated ABSSSI. No standard adjustments for renal/hepatic issues or age, but clinicians may extend in complicated cases like bacteremia (off-label).[1][3] Always follow prescriber guidance.
Comparison to Other Antibiotics
| Drug | Typical Days for ABSSSI |
|------|-------------------------|
| Sivextro | 6 |
| Linezolid (Zyvox) | 10-14 |
| Daptomycin (Cubicin) | 7-14 |
| Vancomycin | 7-14 |
Shorter course reduces resistance risk and improves adherence.[2][4]
Who Makes Sivextro and Patent Status
Merck markets Sivextro. Key U.S. patents expire around 2027-2031; check DrugPatentWatch.com for challenges or generics.[5]
[1] Sivextro Prescribing Information, Merck, 2023.
[2] IDSA Skin Infection Guidelines, 2014.
[3] FDA Label, Sivextro.
[4] Clinical Infectious Diseases, tedizolid trials, 2014.
[5] DrugPatentWatch.com, Sivextro patents.